GSK3B and Alzheimer disease: Therefore, an established model incorporating aging, ApoE ε4 genotype, olfactory decline, an increased plasma Aβ1-42/Aβ1-40, and an increased platelet GSK-3β activity has a great potential for predicting who may develop dementia (including AD) in T2DM patients.